Welcome to Critical Mass, Law.com’s weekly briefing for class action and mass tort attorneys. What impact could the U.S. Supreme Court’s decision not to review a $2.1 billion verdict have on talcum powder cases against Johnson & Johnson? Bayer’s “five-point plan” on Roundup, announced last week, has some unremarkable — and remarkable — points. The federal judge who appointed a diverse team to lead the Zantac multidistrict litigation talked to Law.com about her career.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]